• ICU Medical posted second-quarter GAAP net income of USD 19.1 million, down from USD 35.3 million a year earlier; diluted EPS fell to USD 0.76.
• GAAP revenue edged up 1% from a year earlier to USD 551.7 million; GAAP gross margin widened 5 percentage points to 43%.
• Adjusted EBITDA rose to USD 110 million from USD 100.3 million, while adjusted diluted EPS increased to USD 2.37 from USD 2.10.
• CEO Vivek Jain said Infusion Systems results were ahead of expectations, with the remainder of the business generally in line with expectations.
• Fiscal 2026 guidance raised for GAAP net income to USD 73 million–USD 83 million and adjusted EBITDA to USD 415 million–USD 435 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICU Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805450) on August 06, 2026, and is solely responsible for the information contained therein.